Literature DB >> 4635504

Respiratory diseases in cyclophosphamide-treated mice. I. Increased virulence of Mycoplasma pulmonis.

S H Singer, M Ford, R L Kirschstein.   

Abstract

Mice infected intranasally with Mycoplasma pulmonis were treated with cyclophosphamide, a potent immunologic suppressor. In place of a chronic smouldering infection with little mortality (2%), a rapidly lethal infection with high mortality (66%) was produced. M. pulmonis was able to be isolated from several organs during the course of the unmodified infection. In the infected animals treated with cyclophosphamide, dissemination occurred earlier, and higher titers of mycoplasma were found. Reconstitution experiments with spleen cells from previously infected animals reversed the effect of cyclophosphamide, indicating that immunity plays an important role in containment of the infection and eventual recovery.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4635504      PMCID: PMC422470          DOI: 10.1128/iai.5.6.953-956.1972

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  8 in total

1.  Fatal Japanese encephalitis virus infection in immunosuppresed spider monkeys.

Authors:  N Nathanson; G A Cole
Journal:  Clin Exp Immunol       Date:  1970-01       Impact factor: 4.330

2.  Effect of cyclophosphamide on experimental staphylococcus infection in the rat.

Authors:  R J Sharbaugh; J B Grogan
Journal:  Nature       Date:  1969-11-22       Impact factor: 49.962

3.  Role of serum protective factor (SPF) in Langat virus infection of neonatally thymectomized, cyclophosphamide-treated, or antilymphocyte-treated mice.

Authors:  I S Thind; W H Price
Journal:  J Immunol       Date:  1969-12       Impact factor: 5.422

4.  Potentiation of experimental arbovirus encephalitis by immunosuppressive doses of cyclophosphamide.

Authors:  G A Cole; N Nathanson
Journal:  Nature       Date:  1968-10-26       Impact factor: 49.962

5.  Recovery from primary infection with Langat E5 virus in normal and cyclophosphamide treated mice: relative roles of virus multiplication, interferon, antibody and serum protective factor.

Authors:  I S Thind; W H Price
Journal:  Am J Epidemiol       Date:  1969-05       Impact factor: 4.897

6.  Cross-protection with group B arboviruses in mice treated with cyclophosphamide: role of serum antibody, viremia, and virus multiplication in the brain.

Authors:  I S Thind; W H Price
Journal:  Am J Epidemiol       Date:  1969-01       Impact factor: 4.897

7.  Effect of immunosuppressive drugs on infection in mice by M. marinum (balnei), M. tuberculosis and M. leprae.

Authors:  C C Shepard; M A Redus
Journal:  Int J Lepr Other Mycobact Dis       Date:  1967 Jul-Sep

8.  The effect of cytotoxic agents on the primary immune response to Listeria monocytogenes.

Authors:  S P Tripathy; G B Mackaness
Journal:  J Exp Med       Date:  1969-07-01       Impact factor: 14.307

  8 in total
  12 in total

1.  Effect of cyclophosphamide on infections in mice caused by virulent and avirulent strains of influenza virus.

Authors:  J Hurd; R B Heath
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

2.  Factors in resistance to and recovery from M. pulmonis-induced arthritis in mice.

Authors:  G Taylor; D Taylor-Robinson
Journal:  Ann Rheum Dis       Date:  1977-06       Impact factor: 19.103

3.  Preferential lymphatic growth in bronchus-associated lymphoid tissue in sustained lung inflammation.

Authors:  Peter Baluk; Alicia Adams; Keeley Phillips; Jennifer Feng; Young-Kwon Hong; Mary B Brown; Donald M McDonald
Journal:  Am J Pathol       Date:  2014-03-11       Impact factor: 4.307

4.  Effect of immunosuppression on arthritis in mice induced by Mycoplasma pulmonis.

Authors:  G Taylor; D Taylor-Robinson; G Slavin
Journal:  Ann Rheum Dis       Date:  1974-07       Impact factor: 19.103

5.  In vitro and in vivo activities of QA-241, a new tricyclic quinolone derivative.

Authors:  M Asahara; A Tsuji; S Goto; K Masuda; A Kiuchi
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  Monoclonal antibodies that inhibit mitogenic activity of Mycoplasma pulmonis.

Authors:  Z Lapidot; R Siman-Tov; Y Naot
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

7.  Susceptibility of mice treated with cyclophosphamide to lethal infection with Leptospira interrogans Serovar pomona.

Authors:  B Adler; S Faine
Journal:  Infect Immun       Date:  1976-09       Impact factor: 3.441

8.  Mitogenic activity of Mycoplasma pulmonis. I. Stimulation of rat B and T lymphocytes.

Authors:  Y Naot; S Merchav; E Ben-David; H Ginsburg
Journal:  Immunology       Date:  1979-03       Impact factor: 7.397

9.  Cyclophosphamide pretreatment and protection against malaria.

Authors:  J F Finerty; E P Krehl
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

10.  Effect of cyclophosphamide on experimental Nocardia asteroides infection in mice.

Authors:  B L Beaman; S Maslan
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.